Key Technology, a US manufacturer of process automation systems, has promoted Bret Larreau to the new position of manager of business development. He takes responsibility for building new business alliances and developing acquisition opportunities that will expand Key’s solutions within the pharmaceutical and food manufacturing industries.
Larreau has been with Key Technology for eight years and brings 25 years of automated food processing equipment experience to his position. Prior to this promotion, he was the product marketing manager responsible for Key’s optical sorters.
Before joining Key, he was a senior project manager for Integrated Packaging Systems and prior to that, he worked in engineering, manufacturing management, sales support management and product management for DSI/Stein, part of FMC FoodTech.
‘It’s exciting to make this shift, leveraging my experience in the industry and recent market development activities, to focus on finding new opportunities to improve customers’ operations and grow Key’s business,’ said Larreau.
‘We’ve the resources and the personnel to make new partnerships, acquisitions, and licensing a high priority, while continuing to work closely with existing partners on ongoing projects.’
Key Technology makes a promotion
Bret Larreau becomes manager of business development
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Manufacturing
How intelligent checkweighers offer improved productivity in pharmaceutical manufacturing
Precise weighing, automated reporting and tailored handling help pharmaceutical producers reduce waste, streamline compliance processes and maintain reliable output across demanding production lines
Ingredients
UKHSA to investigate PFAS exposure in UK population as pharma industry faces regulatory scrutiny
The agency's new biomonitoring study will investigate PFAS exposure across the UK, providing evidence as pharmaceutical manufacturers face growing pressure around the use of forever chemicals
Manufacturing
Shilpa CDMO invests $50m to expand peptide manufacturing capacity in India
The CDMO is investing $50m in additional solid-phase peptide synthesis capacity and a new commercial manufacturing line at its Raichur campus, expanding its capabilities to meet demand for GLP-1s and increasingly complex peptide therapeutics across oncology and rare diseases
Pharmaceutical
OGT launches four IVDR-certified CytoCell FISH probes for haematological malignancy diagnostics
The new probes advance OGT’s transition of its CytoCell portfolio from IVDD ahead of the December 2028 Class C deadline, helping laboratories maintain compliant leukaemia and myeloma testing workflows
Pharmaceutical
Pharma’s silent sustainability risk and the supply chain fix
Pharma is making efforts to cut emissions from its own operations: shifting to renewables, upgrading facilities, streamlining logistics²⁰. But a significant share of emissions still hides outside the company’s direct control – yet in plain sight. Now, regulators and investors are turning their focus beyond the factory gates, deep into the value chain. What they’re finding is already reshaping the rules of competitiveness, capital access, and compliance. One of pharma’s most overlooked risks is quietly moving into the foreground. And the time to act is narrowing